← Back to directory
Oncology · 肿瘤科
Medical Oncology肿瘤内科 · Oncología Médica
Live now
Choose your specialist
This specialty has several focused companions, each anchored on its own world-leading clinicians and 2021–2026 evidence. Not sure which one? Start with the generalist and it will point you to the right specialist.
GeneralBiomarker-first oncologyMDT & trialsBreast & blood cancers
Not sure? Start hereDr. Sara M. TolaneyDana-Farber Cancer InstituteLeads HER2-directed and treatment-de-escalation breast trials
Dr. Carl H. JuneUniversity of PennsylvaniaPioneered CAR-T cell therapy for blood cancers
Dr. S. Vincent RajkumarMayo ClinicChairs the IMWG — defines multiple-myeloma diagnosis & treatment
Anemia workupAnemia workupIron / B12 / folateBenign hematology
Dr. Tomas GanzUCLA David Geffen School of MedicineCo-discoverer of hepcidin and erythroferrone — the master iron-regulatory and erythropoiesis-feedback hormones; Landsteiner-Alter Award 2025; hepcidin discovery underpins all modern IDA and anemia-of-chronic-disease therapeutics.
Prof. Martina U. MuckenthalerRuprecht-Karls University HeidelbergEurope's leading scientist on the genetics and molecular pathophysiology of iron disorders; co-author of the definitive 2024 EHA IDA guidelines (HemaSphere 2024).
Dr. Michael AuerbachGeorgetown University School of Medicine; Center for Cancer and Blood Disorders, MarylandClinical Professor at Georgetown; first prospective US study of IV iron in pregnancy (Am J Med 2017); lead author, 2024 Expert Consensus Guidelines on IV Iron (Am J Hematology); co-author 'Iron Deficiency in Adults' JAMA May 2025; ASH IDA guideline panel member.
Prof. Stefano RivellaDivision of Hematology, Children's Hospital of Philadelphia (CHOP)Kwame Ohene-Frempong Endowed Chair in Pediatric Hematology at CHOP; key contributor to understanding iron overload in beta-thalassemia and ineffective erythropoiesis; multiple landmark Blood/JCI papers on iron metabolism in erythroid disorders.
Leukemia & lymphomaLeukemia & lymphomaMultiple myelomaCAR-T & targeted therapy
Dr. Carl H. JuneUniversity of PennsylvaniaPioneered CAR-T for leukemia & lymphoma
Dr. John C. ByrdUPMC Hillman Cancer CenterDrove the BTK-inhibitor revolution in CLL
Dr. S. Vincent RajkumarMayo ClinicChairs the IMWG — multiple-myeloma diagnosis & treatment
Breast cancerBreast cancerBiomarkers (ER/HER2/Oncotype)CDK4/6 & HER2 ADC
Dr. Sara M. TolaneyDana-Farber Cancer InstituteLeads HER2-directed and de-escalation breast-cancer trials
Dr. Javier CortésIOB Institute of Oncology, Madrid/BarcelonaFirst author of DESTINY-Breast03 — T-DXd for HER2+ disease
Dr. Nadia HarbeckLMU University Hospital MunichmonarchE author group — adjuvant abemaciclib in high-risk early breast cancer
Peritoneal surface malignancyPeritoneal surface malignancyCRS+HIPEC candidacyPost-HIPEC microenvironmentDoubt-the-borrowed-benchmark
Dr. David G. SuYale General Surgery Resident → City of Hope Surgical Oncology Fellow (incoming)Yale-trained surgeon-scientist reading the post-HIPEC tumor microenvironment and shaping the multi-institutional consensus that replaces one senior surgeon's opinion in rare peritoneal disease.
This agent is trained only on publicly available medical literature and educational materials. It does not provide individualized medical advice, diagnosis, or prescription. Any decision-making — tests, medications, treatments — must be reviewed and authorized by a licensed clinician. For acute chest pain, syncope, or severe shortness of breath, seek emergency care immediately via your local emergency services.